Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
Items 601–700 of 1,000
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
Richardson, P. G. G., Mitsiades, C., Laubach, J., Schlossman, R., Ghobrial, I., Hideshima, T., Munshi, N., & Anderson, K. (2009) · Core evidence · doi:10.2147/ce.s6002 · Cited by 22
Chanan-Khan, A. A., Lonial, S., Weber, D., Borrello, I., Foà, R., Hellmann, A. R., Dimopoulos, M. A., Swern, A. S., & Knight, R. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1125-7 · Cited by 26
“Both groups received oral dexamethasone (40 mg per day) on days 1–4, 9–12, and 17–20 of each 28-day cycle; after four cycles, dexamethasone was administered on days 1–4 only [8, 9].”
BackgroundMethodInfluentialSelf-citationReshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 22
Jiang, T., Su, H., Li, Y., Wu, Y., Ming, Y., Li, C., Fu, R., Feng, L., Li, Z., Li, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.989032 · Cited by 21
“Lenalidomide combined with high-dose dexamethasone resulted in grade 3–4 infections in 10%–22% of patients with MM (Dimopoulos et al., 2007; Weber et al., 2007).”
BackgroundRecent Advances in the Pathogenesis and Management of Cast Nephropathy (Myeloma Kidney)
Stringer, S. J., Basnayake, K., Hutchison, C. A., & Cockwell, P. (2011) · Bone Marrow Research · doi:10.1155/2011/493697 · Cited by 21
Hultcrantz, M. L., Pfeiffer, R. M., Björkholm, M., Goldin, L. R., Turesson, I., Schulman, S., Landgren, O., & Kristinsson, S. Y. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12724 · Cited by 24
Siena, S., Cutsem, E. V., Li, M., Jungnelius, U., Romano, A., Beck, R. E., Bencardino, K. B., Élez, E., Prenen, H., Sanchis, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062264 · Cited by 22
“Lenalidomide (RevlimidH, Celgene Corporation) is an immunomodulatory agent with antiangiogenic and antineoplastic properties that has demonstrated efficacy and an acceptable toxicity profile in multiple myeloma and myelodysplastic syndromes [24–26].”
BackgroundKneppers, E., Lokhorst, H. M., Eeltink, C., Huls, G. A., Kersten, M. J., Koedam, J., Minnema, M. C., van Oers, M. H. J., Raymakers, R. A. P., Schaafsma, M. R., et al. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.020 · Cited by 21
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis
Boyle, E. M., Fouquet, G., Manier, S., Gauthier, J., Noel, M. P., Borie, C., Facon, T. T. F., Elalamy, I., & Leleu, X. P. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.52 · Cited by 21
“Lenalidomide At diagnosis Zonder (2006) (len–dex) II 21 None 75 [61] Relapse or refractory Dimopoulos et al. (2007) (len–dex) III 176 None 11 [32] Weber et al. (2007) (len–dex) III 177 None 15 [33] Morgan et al. (2007) (len–cyclophosphamide) II 21 Asprin/LMWH/ warfarin 14 [68] Richardson et al.…”
Self-citationClave, E., Douay, C., Coman, T., Busson, M., Bompoint, C., Moins‐Teisserenc, H., Glauzy, S., Carmagnat, M., Gorin, N. C., Toubert, A., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.865182 · Cited by 23
Harada, T., Ozaki, S., Oda, A., Fujii, S., Nakamura, S., Miki, H., Kagawa, K., Takeuchi, K., Matsumoto, T., & Abe, M. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1321-0 · Cited by 21
“Lenalidomide (Len), a potent immunomodulatory drug (IMiD), has begun to be used widely in patients with newly diagnosed, refractory or relapsed multiple myeloma (MM) with encouraging results [1–5].”
BackgroundKhalafallah, A. A., Maiwald, M., Cox, A. D., Burns, D., Bates, G., Hannan, T., Seaton, D., Fernandopulle, B., & Brain, T. (2010) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2010.005 · Cited by 21
Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease
Khatri, N., Patel, B., Kohli, D. R., Solomon, S. S., Bull-Henry, K. P., & Kessler, C. M. (2018) · Haemophilia · doi:10.1111/hae.13419 · Cited by 21
The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes
Palumbo, A. P., Freeman, J., Weiss, L., & Fenaux, P. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.619975 · Cited by 21
“Clinically relevant AEs associated with lenalidomide treatment are hematologic (neutropenia and thrombocytopenia), which are also the most common, and venous thromboembolism (VTE) (when lenalidomide is given in combination with dexamethasone) [2,3,43,44].”
BackgroundResultInfluentialLenalidomide in multiple myeloma: current experimental and clinical data
Cives, M., Milano, A., Dammacco, F., & Silvestris, F. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01735.x · Cited by 21
“Therefore, to improve their outcomes, in the absence of disease progression and toxicity, LEN-DEX treatment should be continued until the best response is achieved (23, 24).”
ResultInfluentialMultiple myeloma: improved outcomes with new therapeutic approaches
Eshaghian, S., & Berenson, J. R. (2012) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3283565c56 · Cited by 20
“The drug was approved in combination with dexamethasone for previously treated multiple myeloma patients based on two large phase III trials (multiple myeloma-009/010) showing its superiority to treatment with the steroid alone [11,12].”
BackgroundMethodImmunomodulatory drugs: a promising clinical ally for cancer immunotherapy
Colley, A., Brauns, T. A., Sluder, A. E., Poznansky, M. C., & Gemechu, Y. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.05.001 · Cited by 23
Rosovsky, R. P. G., Hong, F., Tocco, D., Connell, B., Mitsiades, C. S., Schlossman, R. L., Ghobrial, I. M., Lockridge, L., Warren, D. L., Bradwin, G., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12152 · Cited by 21
“However, the combination of lenalidomide and dexamethasone, which is approved for the treatment of relapsed or relapsed and refractory MM, is associated with an increased VTE risk of approximately 11–15% (Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundResultReactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports
Yoshida, T., Kusumoto, S., Inagaki, A., Mori, F., Ito, A., Ri, M., Ishida, T., Komatsu, H., Iida, S., Sugauchi, F., et al. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0592-y · Cited by 20
Chen, N., Ye, Y., Liu, L., Reyes, J. F., Assaf, M. S., Kasserra, C., Zhou, S. Y., & Palmisano, M. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12081 · Cited by 21
Wang, M., Delasalle, K. B., Giralt, S., & Alexanian, R. (2010) · Hematology · doi:10.1179/102453310x12583347010133 · Cited by 23
Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
Maïga, S., Gomez‐Bougie, P., Bonnaud, S., Gratas, C., Moreau, P., Gouill, S. L., Pellat‐Deceunynck, C., & Amiot, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.186 · Cited by 20
“This result is consistent with clinical observations showing that patients with or without t(4;14) responded equally to LEN plus dexamethasone (Dimopoulos et al, 2007).”
ResultAdvances in multiple myeloma therapy during two past decades
Špıčka, I. (2014) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.05.005 · Cited by 24
“03) [17].”
Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies
Vallet, S., Witzens‐Harig, M., Jaeger, D., & Podar, K. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.656091 · Cited by 21
“Dexamethasone downregulates NK-cell receptors NKG2D and Nkp46, which are required for the NK-cell killing of MM cells [183,117].”
BackgroundInfluentialKatodritou, E., Kyrtsonis, M., Delimpasi, S., Kyriakou, D. S., Symeonidis, A. S., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, Α., Kioumi, A., Zikos, P., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3361-2 · Cited by 23
“Even though the efficacy and safety of the Len/Dex combination is well documented [7, 8, 10], the current study confirms the effectiveness of the combination in the Breal-world^ setting focusing on patients who received the combination in their Fig.”
MethodResultBilich, T., Nelde, A., Bauer, J., Walz, S., Roerden, M., Salih, H. R., Weisel, K. C., Besemer, B., Marcu, A., Lübke, M., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0288-3 · Cited by 20
Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma
Mynott, R. L., & Wallington-Beddoe, C. T. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00074 · Cited by 22
Key regulators of sensitivity to immunomodulatory drugs in cancer treatment
Wang, S., Li, Z., & Gao, S. (2021) · Biomarker Research · doi:10.1186/s40364-021-00297-6 · Cited by 23
Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study
Petrucci, M. T., Calabrese, E., Levi, A., Federico, V., Ceccolini, M., Rizzi, R., Gozzetti, A., Falco, P., Lazzaro, C. R., Martelli, E., et al. (2013) · Tumori Journal · doi:10.1177/030089161309900434 · Cited by 20
Self-citationSchey, S., Brown, S., Tillotson, A., Yong, K., Williams, C. D., Davies, F. E., Morgan, G. J., Cavenagh, J. D., Cook, G., Cook, M. A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13435 · Cited by 22
“…is being increasingly used in de novo disease (Palumbo et al, 2012), maintenance (Attal et al, 2012; McCarthy et al, 2012) and at early relapse (Dimopoulos et al, 2007; Weber et al, 2007), and with lenalidomide-refractory patients often exhibiting myelosuppression at progression, thalidomide…”
BackgroundMethodPomalidomide: A new IMiD with remarkable activity in both multiple myeloma and myelofibrosis
Lacy, M. Q., & Rajkumar, S. V. (2009) · American Journal of Hematology · doi:10.1002/ajh.21610 · Cited by 20
“Lenalidomide and dexamethasone has response rates of 55–60% [22,23] in relapsed myeloma and 90% in newly diagnosed myeloma [24,25].”
BackgroundDuong, V. H., Komrokji, R. S., & List, A. F. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620711435659 · Cited by 22
How I treat elderly patients with plasma cell dyscrasias
Gavriatopoulou, M., Fotiou, D., Ntanasis‐Stathopoulos, I., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2018) · Aging · doi:10.18632/aging.101707 · Cited by 20
Self-citationAllogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs
Festuccia, M. B., Martino, M. V., Ferrando, F., Messina, G., Moscato, T., Fedele, R., Boccadoro, M., Giaccone, L., & Bruno, B. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036735 · Cited by 20
“Overall, despite the limitation of retrospective studies, Len appears to be the most promising drug as salvage after alloSCT enforcing the hypothesis that Len enhances GvM by interacting with donor T cells [67-69].”
Memory loss during lenalidomide treatment: a report on two cases
Rollin‐Sillaire, A., Delbeuck, X., Pollet, M., Mackowiak, M., Lenfant, P., Noël, M., Facon, T. T. F., Leleu, X. P., Pasquier, F., & Rhun, É. L. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-41 · Cited by 19
Self-citationImmunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice
Castelli, R., Cannavò, A., Conforti, F., Grava, G., & Cortelezzi, A. (2012) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2012.658921 · Cited by 19
Dytfeld, D., Rosebeck, S., Kandarpa, M., Mayampurath, A. M., Mellacheruvu, D., Alonge, M. M., Ngoka, L. C. M., Jasielec, J. K., Richardson, P. G. G., Volchenboum, S. L., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13394 · Cited by 20
“…following the incorporation of immunomodulatory drugs, such as thalidomide, lenalidomide and pomalidomide, and proteasome inhibitors, including bortezomib and carfilzomib, into treatment strategies (Richardson et al, 2002, 2005; Dimopoulos et al, 2007; Harousseau et al, 2009; Dytfeld et al, 2011).”
BackgroundReece, D. E., Masih‐Khan, E., Atenafu, E. G., Jimenez-Zepeda, V. H., Anglin, P., Chen, C. I., Kukreti, V., Mikhael, J. R., & Trudel, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.13100 · Cited by 19
Presentation and risk stratification – improving prognosis for patients with multiple myeloma
Lonial, S. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70007-4 · Cited by 24
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Patriarca, F. F., Petrucci, M. T., Bringhen, S., Baldini, L., Caravita, T., Corradini, P., Corso, A., Raimondo, F. D., Falcone, A. P., Ferrara, F., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01179.x · Cited by 21
“Toxic effects related to lenalidomide in association with dexamethasone or other drugs are mainly neutropenia, thrombocytopenia, infections and thrombosis (77, 78, 90).”
BackgroundSelf-citationMalard, F., Harousseau, J., & Mohty, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.005 · Cited by 20
Self-citationKiesewetter, B., Cherny, N. I., Boissel, N., Cerisoli, F., Dafni, U. G., de Vries, E. G. E., Ghia, P., Gökbuget, N., González‐Calle, V., Huntly, B. J. P., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000611 · Cited by 24
Tochigi, T., Miyamoto, T., Hatakeyama, K., Sakoda, T., Ishihara, D., Irifune, H., Shima, T., Kato, K., Maeda, T., Ito, T., et al. (2020) · Blood · doi:10.1182/blood.2019003749 · Cited by 20
Lenalidomide in Multiple Myeloma—A Practice Guideline
Chen, C., Baldassarre, F. G., Kanjeekal, S. M., Herst, J. A., Hicks, L. K., & Cheung, M. C. (2013) · Current Oncology · doi:10.3747/co.20.1252 · Cited by 19
A Benefit–Risk Analysis Approach to Capture Regulatory Decision‐Making: Multiple Myeloma
Raju, G. K. P., Gurumurthi, K., Domike, R., Kazandjian, D. G., Landgren, O., Blumenthal, G. M., Farrell, A. T., Pazdur, R., & Woodcock, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.871 · Cited by 19
Cella, D. F., McKendrick, J., Kudlac, A., Palumbo, A. P., Oukessou, A., Vij, R., Zyczynski, T. M., & Davis, C. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3469-4 · Cited by 19
Novel insights into the mechanism of action of lenalidomide
Semeraro, M., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28386 · Cited by 20
The Era of Combination Therapy in Myeloma
Lonial, S., & Kaufman, J. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.6967 · Cited by 21
Boyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 19
“…15 years, the use of IMiDs together with proteasome inhibitors has transformed the therapeutic landscape and outcome of patients with MM. Lenalido-mide plus dexamethasone (Rd) was superior to dexamethasone alone in two phase III trials involving patients with relapsed/refractory MM (RRMM) [9, 10].”
BackgroundDifferential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
Hussain, M., Yellapragada, S. V., & Hadidi, S. A. (2023) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s272703 · Cited by 27
“105 Daratumumab is used in upfront in newly diagnosed MM as well as RRMM. Isatuximab is another anti-CD38 monoclonal antibody with a different mechanism of action from daratumumab.”
InfluentialBlimark, C. H., Veskovski, L., Westin, J., Rödjer, S., Brune, M. L., Hjorth, M., Holmberg, E. C., Andersson, P., & Mellqvist, U. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01634.x · Cited by 18
“bortezomib (4), thalidomide (5), lenalidomide (6), standard-dose melphalan ⁄prednisone (MP), bendamustine (7) or multi-drug combinations (8).”
BackgroundThe DAC system and associations with multiple myeloma
Ocio, E. M., & Miguel, J. F. S. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9589-x · Cited by 20
“In this regard, several studies have demonstrated the activity of the proteasome inhibitor bortezomib [5] and the immunomodulatory agents thalidomide [6] and lenalidomide [7, 8] in relapsed/ refractory MM patients.”
BackgroundSelf-citationOffidani, M., Corvatta, L., Polloni, C., Gentili, S., Mele, A., Rizzi, R., Catarini, M., Caraffa, P., Samorì, A., Blasi, N., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1217-0 · Cited by 19
Harada, T., Ozaki, S., Oda, A., Tsuji, D., Ikegame, A., Iwasa, M., Udaka, K., Fujii, S., Nakamura, S., Miki, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083905 · Cited by 20
“[25–27] Len induces not only direct cytotoxic effects on MM cells but also immunomodulatory, anti-inflammatory, and anti-angiogenic effects on accessory cells surrounding MM cells in the bone marrow [28].”
BackgroundMorgan, G. J. (2010) · Blood Reviews · doi:10.1016/s0268-960x(10)70006-0 · Cited by 20
Walavalkar, V., Adey, D., Laszik, Z. G., & Jen, K. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.01.014 · Cited by 18
Charliński, G., Grząśko, N., Jurczyszyn, A. J., Janczarski, M., Szeremet, A., Waszczuk‐Gajda, A., Bernatowicz, P., Świderska, A., Guzicka‐Kazimierczak, R., Lech‐Marańda, E., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13106 · Cited by 19
Uno, S., Goto, R., Suzuki, K., Iwasaki, K., Takeshima, T., & Ohtsu, T. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1686870 · Cited by 18
Choi, H., Kim, Y., Kang, D., Kwon, A., Kim, J., Kim, J. M., Park, S., Kim, Y., Min, C., & Kim, M. (2020) · Cell Proliferation · doi:10.1111/cpr.12819 · Cited by 17
Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments
Geis, M., Nowotny, B., Bohn, M.-D., Kouhestani, D., Einsele, H., Bumm, T. G. P., & Stuhler, G. (2021) · Communications Biology · doi:10.1038/s42003-020-01558-0 · Cited by 20
Seefat, M. R., Cucchi, D. G. J., Dirven, S., Groen, K., Zweegman, S., & Blommestein, H. M. (2021) · Cancers · doi:10.3390/cancers13225606 · Cited by 19
“70 2nd line: USD 154,979 3rd line: USD 159,030 2nd line: USD 211,458 3rd line: USD 252,293 Rd MM-009 and 010 [42,43] KRd ASPIRE trial [47] Median prior LOTs: 2 Carlson et al.”
BackgroundInfluentialManagement of the adverse effects of lenalidomide in multiple myeloma
González, A. P. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0104-8 · Cited by 18
Fragoulakis, V., Maniadakis, N., Ψαλτοπούλου, Θ., & Kastritis, E. (2013) · Cancer Management and Research · doi:10.2147/cmar.s43373 · Cited by 19
“The model simulates the progress and outcomes of a large hypothetical patient population (eg, 1000), consisting of individuals with characteristics and clinical histories similar to those of patients enrolled in the MM-009 and MM-010 trials.(18,19) MM-009 and MM-010 were two identical multicenter, pivotal, double-blin…”
A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma
Jourdan, É., Leblond, V., Maisonneuve, H., Benhadji, K. A., Hossain, A. M., Nguyen, T. S., Wooldridge, J. E., & Moreau, P. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.861066 · Cited by 18
Zhou, F., Guo, L., Shi, H., Lin, C.-H., & Hou, J. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.005 · Cited by 18
Montefusco, V., Mussetti, A., Rezzonico, F., Maura, F., Pennisi, M., Philippis, C. D., Capecchi, M., & Corradini, P. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.183 · Cited by 18
Falk, I. J., Lund, J., Gréen, H., Gruber, A., Alici, E., Lauri, B., Blimark, C. H., Mellqvist, U., Swedin, A., Forsberg, K., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3481-8 · Cited by 18
“Len, which is approved for the treatment of relapsed or refractory MM (RRMM) largely based on the results of two phase III clinical trials [11, 12], undergoes limited metabolism, and is mainly excreted via the kidneys [13].”
BackgroundGlobal Myeloma Trial Participation and Drug Access in the Era of Novel Therapies
Fatoki, R. A., Koehn, K., Kelkar, A. H., Hadidi, S. A., Mehra, N., Mian, H. S., Landgren, O., Kazandjian, D. G., Hoffman, J. E., Sborov, D. W., et al. (2022) · JCO Global Oncology · doi:10.1200/go.22.00119 · Cited by 20
Dytfeld, D., Griffith, K. A., Friedman, J. D., Lebovic, D. J., Harvey, C., Kaminski, M. S., & Jakubowiak, A. J. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.567316 · Cited by 17
Kristinsson, S. Y., Björkholm, M., Schulman, S., & Landgren, O. (2011) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.11.002 · Cited by 21
Guglielmelli, T., Bringhen, S., Rrodhe, S., Gay, F., Cavallo, F., Berruti, A., Montefusco, V., Piro, E., Benevolo, G., Petrucci, M. T., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.026 · Cited by 18
Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma
Bila, J., Sretenović, A., Jelicic, J., Tos̆ić, N., Glumac, I., Fekete, M. D., Antic, D. A., Todorović, M., Marković, O., Milojevic, Z., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.007 · Cited by 18
Population pharmacokinetics of lenalidomide in multiple myeloma patients
Guglieri-López, B., Pérez‐Pitarch, A., Moes, D. J. A. R., Porta-Oltra, B., Martí, M. C., Guchelaar, H., & Merino‐Sanjuán, M. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3228-y · Cited by 17
“Two phase III studies, MM-009 and MM-010, were designed to compare lenalidomide plus dexamethasone combination therapy with dexamethasone monotherapy in previously treated patients with multiple myeloma [4, 5].”
BackgroundIriyama, N., Miura, K., Hatta, Y., Kobayashi, S., Uchino, Y., Kurita, D., Sakagami, H., Takahashi, H., Sakagami, M., Kobayashi, Y., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5920 · Cited by 17
Alhuraiji, A., Naqvi, K. Z., Huh, Y. O., Ho, C., Verstovšek, S., & Bose, P. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1264 · Cited by 17
“It is used most widely in MM, as part of two- [9, 10, 13] and three- [14–17] drug induction regimens, in both the frontline and relapsed/refractory settings, as well as in maintenance [18–20], usually as a single agent.”
BackgroundDesign and synthesis of new lenalidomide analogs via Suzuki cross‐coupling reaction
Xiao, D., Wang, Y., Wang, H., Zhou, Y., Li, J. X., Lu, W. P., & Jin, J. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.201900376 · Cited by 17
Berdeja, J. G., Gregory, T. K., Faber, E. A., Hart, L. L., Mace, J. R., Arrowsmith, E. R., Flinn, I. W., & Matous, J. (2021) · American Journal of Hematology · doi:10.1002/ajh.26088 · Cited by 17
Party, T. K. M. M. W., Lee, S. S., Suh, C., Kim, B.-S., Chung, J.-S., Joo, Y., Ryoo, H.-M., Do, Y. R., Jin, J., Kang, H. J., et al. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0943-z · Cited by 17
Observations of Second Primary Malignancy in Patients With Multiple Myeloma
Ormerod, A., Fausel, C. A., Abonour, R., & Kiel, P. J. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.11.003 · Cited by 18
New pharmacotherapy options for multiple myeloma
Mina, R., Cerrato, C., Bernardini, A., Aghemo, E., & Palumbo, A. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1115016 · Cited by 18
Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
Richardson, P. G. G., Laubach, J. P., Mitsiades, C. S., Schlossman, R. L., Doss, D. S., Colson, K., McKenney, M., Noonan, K., Warren, D. L., Ghobrial, I. M., et al. (2010) · PubMed · Cited by 17
Role of Endothelial Cells and Fibroblasts in Multiple Myeloma Angiogenic Switch
Ribatti, D., & Vacca, A. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_5 · Cited by 19
Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide
Schoenbeck, K. L., & Wildes, T. M. (2020) · Clinical Interventions in Aging · doi:10.2147/cia.s196087 · Cited by 18
“2%) than placebo.(38) Interim multivariate”
Lenalidomide and its role in the management of multiple myeloma
Falco, P., Cavallo, F., Larocca, A., Liberati, A. M., Musto, P., Boccadoro, M., & Palumbo, A. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.6.865 · Cited by 17
Immunomodulatory Agents for Multiple Myeloma
Minařík, J., & Ševčíková, S. (2022) · Cancers · doi:10.3390/cancers14235759 · Cited by 17
Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
Parekh, D. S., Tiger, Y. K., Jamouss, K. T., Hassani, J., Zerdan, M. B., & Raza, S. (2024) · Cancers · doi:10.3390/cancers16172931 · Cited by 18
“More than half the patients developed CRS, mostly grade 1 [32].”
BackgroundResultBurnette, B. L., Dispenzieri, A. A., Kumar, S. K., Harris, A. M., Sloan, J. A., Tilburt, J. C., Kyle, R. A., & Rajkumar, S. V. (2013) · Cancer · doi:10.1002/cncr.28340 · Cited by 18
“Although earlier experiences with maintenance after both conventional chemotherapy and high-dose therapy had previously been disappointing, the development of the immunomodulating agents thalidomide and lenalidomide as well as the proteasome inhibitor bortezomib signaled the introduction of drugs with greater activity…”
BackgroundTreatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment
Dimopoulos, M. A., Terpos, E., Goldschmidt, H., Alegre, A. M., Mark, T. M., & Niesvizky, R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.009 · Cited by 17
Self-citationReview of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide
Mariz, J., & Esteves, G. V. (2012) · Current Opinion in Oncology · doi:10.1097/01.cco.0000410243.84074.dc · Cited by 18
Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis
Baz, R., Patel, M. P., Finley-Oliver, E., Lebovic, D. J., Hussein, M. A., Miller, K. C., Wood, M., Sher, T., Lee, K. P., & Chanan-Khan, A. A. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003721342 · Cited by 16
Lenalidomide in multiple myeloma: current role and future directions
Zeldis, J. B., Knight, R., Jacques, C. J., Tozer, A., & Bizzari, J.-P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003645611 · Cited by 16
“001 by log-rank test) was observed for the lenalidomide plus dexamethasone treatment group, despite crossover [10,11].”
BackgroundMethodInfluentialSelf-citationRenal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma
Ludwig, H., & Zojer, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.31 · Cited by 16
“Experience with this agent in patients with high serum creatinine levels is, however, limited, because these individuals were excluded from initial trials of lenalidomide”
BackgroundImmunomodulating antibodies and drugs for the treatment of hematological malignancies
Houot, R., Kohrt, H. E. K., Goldstein, M. J., & Levy, R. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9274-3 · Cited by 16
“Potent antitumor efficacy of thalidomide [58] and lenalidomide [59, 60] was first demonstrated in myeloma patients.”
BackgroundClinical Grade “SNaPshot” Genetic Mutation Profiling in Multiple Myeloma
O’Donnell, E., Mahindra, A. K., Yee, A. J., Nardi, V., Birrer, N., Horick, N., Borger, D. R., Finkelstein, D. M., Iafrate, J., & Raje, N. S. (2014) · EBioMedicine · doi:10.1016/j.ebiom.2014.11.008 · Cited by 16
“…ourna l homepage: www.eb iomed ic ine.com Original Article Clinical Grade “SNaPshot” Genetic Mutation Profiling in Multiple Myeloma Elizabeth O'Donnell, Anuj Mahindra, Andrew J. Yee, Valentina Nardi, Nicole Birrer, Nora Horick, Darrell Borger, Dianne Finkelstein, John A. Iafrate, Noopur Raje ⁎”
BackgroundNiesvizky, R., & Badros, A. Z. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0112 · Cited by 16
Qiao, M., Wu, D., Carey, M., Zhou, X., & Zhang, L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143206 · Cited by 16
“The third is chemotherapy withthe following drug combinations: 1,bortezomib, melphalan, andprednisone, with an estimated overall survival of 83% at 30 months [2]; 2,lenalidomide plus low-dose dexamethasone,with 82% survival at two years[3];and 3,melphalan, prednisone and lenalidomide, with90% survival at 2 years[4].”
BackgroundInfluentialUpdates on thrombotic events associated with multiple myeloma
Fotiou, D., Gavriatopoulou, M., Ntanasis‐Stathopoulos, I., Migkou, M., Dimopoulos, M. A., & Terpos, E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1604214 · Cited by 16
“…58% Fouquet et al., 2013 (n = 200) [29] R-based regimens ASA or LMWH NDMM 9.4% RRMM 4.5% Bagratuni et al., 2013 [66] R ASA 6% R-NDMM 9.4% R-RRMM 4.5% Dimopoulos et al., 2007 [30] RD- RRMM None stated 11.4% Placebo – RRMM 4.6% Dimopoulos et al., 2014 [31] RD 12.7% Rajkumar et al., 2010 Rd NDMM…”
BackgroundInfluentialSelf-citationFonseca, R., & Rajkumar, S. V. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.046 · Cited by 16
Lenalidomide‐associated pneumonitis in patients with plasma cell dyscrasias
Zagouri, F., Ρούσσου, Μ., Kastritis, E., Koureas, A. P., Tsokou, E., Migkou, M., Gavriatopoulou, M., Nikitas, N., Gkotzamanidou, M. A., Terpos, E., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22135 · Cited by 16
Self-citationSrinivasan, S., & Schiffer, C. A. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.06.024 · Cited by 16
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.